Optimizing Contraception for the HIV-positive Woman
The ideal contraceptive for an HIV-positive woman prevents pregnancy as well as transmission of HIV and STDs. Dual contraception using condoms plus an additional contraceptive appears to be the best strategy.
The following represent good contraceptive choices in addition to condoms:
Combined hormonal contraception (pill, patch and ring) and progestin-only pills may decrease hormone levels in women taking some antiretroviral therapies, but are still considered safe (MEC cat. 2)
If the patient is on fosamprenavir, avoid hormonal contraception; it may reduce efficacy of the antiretroviral
Contraceptive implants are highly effective and benefits outweigh risks in HIV positive women (MEC cat. 2)
Theoretical interactions between multiple antiretrovirals and implants may reduce effectiveness
Injectable depot medroxyprogesterone acetate (DMPA) is safe and effective (MEC cat. 1) and does not appear to have interactions with antiretrovirals
Intrauterine devices, both copper containing and levonorgestrel-releasing, are safe (MEC cat. 1) for women with HIV, with no known drug interactions with antiretrovirals
Limited data suggest a low risk of pelvic inflammatory disease and no changes in genital shedding of HIV RNA
Condoms effectively reduce transmission of HIV between discordant partners but do not represent optimal contraception, with an annual pregnancy rate of over 15% per year. Dual contraception with any of the above options are safe in HIV positive women, assuming they meet the usual health criteria for use. Counseling should emphasize that use of any contraception does not take the place of condom use for prevention of transmission.
HIV infection does not pose a barrier to sterilization, which remains an appropriate contraceptive option
Emergency contraception including hormone based (progestin-only pills, ulipristal acetate, combined oral contraceptives) and the copper IUD should be offered to HIV positive women whenever appropriate
Spermicides and diaphragms with spermicide are not recommended
Nonoxynol-9, the active ingredient in most formulations, may increase the likelihood of HIV transmission to a partner
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan